NCT03072381.
Study name | PEAK platelet rich plasma injection treatment for chronic lateral epicondylosis |
Methods | Parallel 2‐arm double‐blind randomised controlled trial |
Participants |
Inclusion criteria
Exclusion criteria
|
Interventions |
Platelet‐rich plasma group
Participants will receive a single ultrasound‐guided intratendinous (common extensor tendon origin) injection of up to 3 mL of autologous PEAK platelet‐rich plasma Glucocorticoid control group Participants will receive a single ultrasound‐guided intratendinous injection of approximately (may be limited by tendon/soft tissue limitations of the subject) 2 mL of 1% lidocaine + 1 mL of 40 mg Kenalog (triamcinolone hexacetonide, 40 mg/mL) at Week 0 |
Outcomes |
Primary outcome measure
Secondary outcome measures
|
Starting date | March 2017 |
Contact information | John J. Wilson, MD; MS608‐440‐6543; wilson@ortho.wisc.edu Kenneth S. Lee, MD; 608‐263‐8183; klee2@uwhealth.org |
Notes | Status: recruiting ClinicalTrials.gov (accessed 26 July 2019) |